18F-氟雌二醇PET/CT评估乳腺癌雌激素受体状态及其瘤内异质性
回顾性纳入46例女性患者共50个经组织学证实的浸润性乳腺癌病灶,均接受18F-FES与18F-FDG PET/CT。F-FES摄取与ER、孕激素受体、人表皮生长因子受体2表达一致性良好(P<0.001)。ROC曲线确定鉴别ER阳性与阴性病灶的最佳阈值为SUVmax 1.82(敏感度88.2%、特异度87.5%)和SUVmean 1.21(敏感度85.3%、特异度93.7%)。
要点
- F-FES PET/CT鉴别ER阳性与阴性病灶的SUVmax阈值为1.82,敏感度88.2%、特异度87.5%。
- SUVmean阈值1.21的敏感度85.3%、特异度93.7%,用SUVmean代替SUVmax相关性略好。
- 简化的异质性指数-FES可观察ER异质性,复发/转移患者及非乳腺部位病灶异质性可能更大。
核心结论
- F-FES PET/CT是评估乳腺癌患者ER表达可行的无创方法。
- 由于存在瘤内异质性,F-FES PET/CT可能更好地反映ER表达,尤其在治疗后的转移患者中,从而辅助制定个体化治疗决策。
研究设计与样本
- 回顾性纳入本中心46例女性患者共50个经组织学证实的浸润性乳腺癌病灶,均接受18F-FES与18F-FDG PET/CT,所有入组患者计划接受活检。
主要发现
- F-FES摄取与ER、孕激素受体、人表皮生长因子受体2表达一致性良好(P<0.001),用SUVmean代替SUVmax可提供略好的相关性。
- ROC曲线分析确定F-FES PET/CT鉴别ER阳性与阴性病灶的最佳阈值为SUVmax 1.82(敏感度88.2%、特异度87.5%)和SUVmean 1.21(敏感度85.3%、特异度93.7%)。
- 简化的异质性指数-FES可简便观察ER异质性,结果提示复发/转移患者及位于乳腺以外部位的病灶异质性可能更大。
关键数值与推荐
- F-FES PET/CT鉴别ER阳性与ER阴性病灶的SUVmax最佳阈值为1.82,敏感度88.2%、特异度87.5%。
- F-FES PET/CT鉴别ER阳性与ER阴性病灶的SUVmean最佳阈值为1.21,敏感度85.3%、特异度93.7%。
- F-FES摄取与ER、孕激素受体、人表皮生长因子受体2表达的一致性检验P<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The aim of this study was to investigate the clinical value of F-fluoroestradiol (F-FES) PET/CT in the assessment of the estrogen receptor (ER) and its intratumoral heterogeneity in breast cancer patients. METHODS: Forty-six female patients (50 lesions) with histologically confirmed invasive breast cancer who underwent both F-FES and F-FDG PET/CT in our center were retrospectively included. All the patients enrolled were scheduled to undergo biopsy. The F-FES and FDG uptakes were compared with pathological features (tumor size, ER, progesterone receptor, human epidermal growth factor receptor 2, and Ki67%). The optimal threshold to discriminate ER-positive and ER-negative lesions was determined by receiver operating characteristic curve analysis. Furthermore, we observed the intratumoral heterogeneity by a heterogeneity index (SUVmax/SUVmean) and compared the results with the Chang-Gung Image Texture Analysis. RESULTS: There was good agreement between F-FES uptake and ER, progesterone receptor, and human epidermal growth factor receptor 2 expression (P < 0.001), and the use of SUVmean instead of SUVmax can provide a slightly better correlation. The optimal threshold for F-FES PET/CT to discriminate between ER-positive and ER-negative lesions, as determined by receiver operating characteristic curve analysis, was an SUVmax of 1.82 (sensitivity = 88.2% and specificity = 87.5%) and SUVmean of 1.21 (sensitivity = 85.3% and specificity = 93.7). Our simplified heterogeneity index-FES can easily observe ER heterogeneity. In addition, our results suggested that recurrent/metastatic patients and lesions located other than breast might have greater heterogeneity. CONCLUSIONS: F-FES PET/CT is a feasible, noninvasive method for assessing ER expression in breast cancer patients. Because intratumoral heterogeneity exists, F-FES PET/CT might better reflect the ER expression, especially in metastatic patients after treatment, thus assisting in making individualized treatment decisions.
引用
- Yang Z, Sun Y, Xu X, et al. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT. Clin Nucl Med. 2017. PMID: 28221191. doi:10.1097/RLU.0000000000001587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。